Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC

Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic – Results published in Journal of Thoracic Oncology Clinical and Research Reports June 23, 2022 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology Clinical and Research Reports that demonstrates their blood 5-microRNA signature (miRisk) to predict survival following immunotherapy in advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression. “The miRisk score represents an immune focused biomarker that is specifically predictive of response...

Hummingbird Diagnostics Developing miRNA-Based Immunotherapy Predictor on Heels of Positive Study

Apr 07, 2022 | Molika Ashford NEW YORK – New research published last week by scientists from Germany’s Hummingbird Diagnostics and collaborators suggests that blood-borne microRNAs (miRNAs) may enable better personalization of cancer immunotherapy. In the study, appearing in the Nature partner journal Precision Oncology, the investigators used whole-blood miRNA profiling to develop a five-miRNA risk score that is predictive of overall survival in stage IV non-small cell lung cancer patients following immunotherapy — outperforming PD-L1 expression, which is currently the most established biomarker for guiding the use of anti-PD-1 agents. Hummingbird now hopes to commercialize a test based on this biomarker signature to guide immunotherapy in lung...

Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

 March 31, 2022 A blood-based signature of five microRNAs demonstrated the ability to predict OS of patients with lung cancer receiving immunotherapy and stratify them for treatment, according to a study published in npjPrecision Oncology.  Researchers reported that because the signature appears to work from a single timepoint before treatment, it differs from classical circulating tumor DNA-based assays, where blood at baseline is typically dynamically compared with follow-up samples. “Importantly, the signature does not require any prior tumor tissue analysis and could be used in an ‘off-the-shelf’ manner,” Bruno R. Steinkraus, PhD, chief scientific officer at Hummingbird Diagnostics, told Healio. “We believe our test could...

Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology

—Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy— —Blood-based test holds potential for broad applicability for the management of patients with cancer—March 31, 2022 05:00 AM Eastern Daylight Time  March 31, 2022 05:00 AM Eastern Daylight Time  HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA (miRNA) biomarker signature that offers the prospect of a blood-based companion diagnostic...

Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution

La Vista, NE – January 10, 2022 Streck today announced a partnership with Ceres Nanosciences to distribute Nanotrap® Magnetic Virus Particles that provide rapid viral concentration directly from raw sewage. This product dramatically reduces the time and effort required to test wastewater samples for COVID-19 surveillance. Wastewater surveillance can act as an early-warning system for COVID-19 “hotspots” within a community. The Ceres Nanotrap Magnetic Virus Particles facilitate a streamlined workflow, improved sensitivity, and reduced time to results. Nanotrap Magnetic Virus Particles are For Research Use Only. Not for use in diagnostic procedures. Traditional methods for concentration of virus from wastewater are...

Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative

MANASSAS, Virginia – November 9, 2021 Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine new wastewater-based epidemiology centers of excellence, as part of the April 2021 $8.2 million award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. Wastewater-based epidemiology can help communities monitor infection dynamics for SARS-CoV-2 and can serve as an early-warning system for the virus in a population, but widespread implementation has been stymied by lack of robust, high-throughput viral concentration methods.​ Ceres’ Nanotrap® Magnetic Virus Particles address...

1 2 3 7
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.


For additional information, please contact: